终末期肾病患者经导管肾去交感神经术的心血管保护概念验证研究
本研究在9例终末期肾病(ESKD)透析患者中评估经导管肾去交感神经术(RDN)对交感神经活性和左心室质量的影响。结果显示RDN后12个月肌肉交感神经活性频率和左心室质量显著降低,动态及诊室血压也下降。提示RDN可能为ESKD患者提供心血管保护。
要点
- RDN可显著降低ESKD患者MSNA频率和左心室质量。
- RDN后12个月动态血压和诊室血压均显著下降。
- 至少50%患者血压下降具有临床意义并持续12个月。
核心结论
- 经导管RDN显著降低ESKD患者MSNA、左心室质量和系统血压。
研究设计与样本
- 前瞻性概念验证研究,纳入9例ESKD透析患者(6例血液透析,3例腹膜透析),透析龄≥11个月,接受EnligHTN系统RDN。
- 于非透析日收集基线、RDN后1、3、12个月数据。
主要发现
- 基线时MSNA和血浆去甲肾上腺素浓度显著升高,9例中8例存在左心室肥厚。
- RDN后12个月MSNA频率降低-12.2 bursts/min(95% CI -13.6至-10.7),左心室质量降低-27 g/m2(95% CI -47至-8)。
- RDN后12个月动态平均血压降低:收缩压-24 mm Hg(95% CI -42至-5),舒张压-13 mm Hg(95% CI -22至-4)。
- 诊室血压在RDN后1个月即降低:收缩压-25 mm Hg(95% CI -45至-5),舒张压-13 mm Hg(95% CI -24至-1)。
- 至少50%患者动态和诊室血压在12个月内均有临床显著下降。
临床怎么用
- 对于ESKD透析患者,RDN可能作为降低交感神经活性和改善心血管重构的辅助治疗选择。
- 需注意本研究为小样本概念验证,RDN的临床获益需更大规模研究证实。
局限性
- 样本量小(9例),为非对照概念验证研究。
- 随访时间12个月,长期疗效和安全性未知。
- 未报告假手术对照或盲法设计细节(除盲法分析外)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Sympathetic neural activation is markedly increased in end-stage kidney disease (ESKD). Catheter-based renal denervation (RDN) reduces sympathetic overactivity and blood pressure in resistant hypertension. We investigated the effect of RDN on sympathetic neural activation and left ventricular mass in patients with ESKD. METHODS: Nine ESKD (6 hemodialysis and 3 peritoneal dialysis) patients with dialysis vintage of ≥11 months were treated with RDN (EnligHTN system). Data were obtained on a nondialysis day; at baseline, 1, 3, and 12 months post-RDN. RESULTS: At baseline sympathetic neural activation measured by muscle sympathetic nervous activity (MSNA) and plasma norepinephrine concentrations were markedly elevated. Left ventricular hypertrophy (LVH) was evident in 8 of the 9 patients. At 12 months post-RDN, blind analysis revealed that MSNAfrequency (-12.2 bursts/min1, 95% CI [-13.6, -10.7]) and LV mass (-27 g/m2, 95% CI [-47, -8]) were reduced. Mean ambulatory BP (systolic: -24 mm Hg, 95% CI [-42, -5] and diastolic: -13 mm Hg, 95% CI [-22, -4]) was also reduced at 12 months. Office BP was reduced as early as 1 month (systolic: -25 mm Hg, 95% CI [-45, -5] and diastolic: -13 mm Hg, 95% CI [-24, -1]). Both ambulatory and office BP had clinically significant reductions in at least 50% of patients out to 12 months. DISCUSSION: Catheter-based RDN significantly reduced MSNA and LV mass as well as systemic BP in this group of patients with ESKD.
引用
- Hoye NA, Wilson LC, Wilkins GT, et al. Endovascular Renal Denervation in End-Stage Kidney Disease Patients: Cardiovascular Protection-A Proof-of-Concept Study. Kidney Int Rep. 2017. PMID: 29270493. doi:10.1016/j.ekir.2017.04.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。